RecruitingNCT05746182

Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

Sponsor

University of California, San Francisco

Enrollment

300 participants

Start Date

Apr 7, 2023

Study Type

OBSERVATIONAL

Conditions

Pancreatic Neuroendocrine Neoplasm

Summary

This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, San Francisco (UCSF)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is offering genetic testing to people with pancreatic neuroendocrine tumors (PanNETs) — a rare type of pancreatic cancer — to find out how many carry inherited gene mutations that may have caused their cancer. This could help with family screening and treatment planning. **You may be eligible if...** - You have been diagnosed with a pancreatic neuroendocrine tumor (confirmed by biopsy) - You are 18 years or older - You are willing to participate in the genetic testing process **You may NOT be eligible if...** - You cannot provide informed consent - You have an active blood cancer (hematologic malignancy) - You have had an allogeneic bone marrow or stem cell transplant - You do not speak one of the supported languages for genetic testing (English, Korean, Japanese, Vietnamese, Russian, Tagalog, Farsi, Spanish, Cantonese, Mandarin, or Arabic) Talk to your doctor to see if this trial is right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Print for Your Doctor Check Your Eligibility

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTHereditary Cancer Panel

UCSF's Internal Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified Expanded Hereditary Cancer Panel will be employed which measures a minimum 88 genes

Locations(3)

University of California, Los Angeles

Los Angeles, California, United States

Univeristy of California, San Diego

San Diego, California, United States

University of California, San Francisco

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05746182

Related Trials

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

NCT062020661 location

A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET

NCT065929891 location